Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ALX-0061

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Single-Domain Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
IntroductionThe pleiotropic cytokine interleukin-6 (IL-6) plays an important role in the pathogenesis of different diseases… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
2014
2014
FRI0329 Impact of Clinical Remission on Physical Function in Patients with Rheumatoid Arthritis Treated with Alx-0061: Post-Hoc Analysis of Phase I/Ii Data
Background ALX-0061 is a monovalent IL-6R targeting Nanobody, inhibiting signaling via soluble and membrane IL-6R. The safety… Expand
2014
2014
Novartis' lung cancer ALK inhibitor approved
Regulators have backed Janssen’s first-in-class, anti-interleukin-6 (IL-6) Sylvant (siltuximab) for multicentric Castleman’s… Expand
2013
2013
OP0043 Twenty-Four Weeks of Treatment with a Novel Anti-IL-6 Receptor Nanobody® (ALX-0061) Resulted in 84% ACR20 Improvement and 58% DAS28 Remission in a Phase I/Ii Study in RA
Background ALX-0061 is a monovalent IL-6R targeting Nanobody. It inhibits signalling via soluble and membrane IL-6R. PK/PD… Expand
2013
2013
FRI0021 Alx-0061, an anti-IL-6r nanobody® for therapeutic use in rheumatoid arthritis, demonstrates in vitro a differential biological activity profile as compared to tocilizumab
Background Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor, which… Expand
2012
2012
preclinical Development of Alx-0061, an Anti-il-6r Nanobody® for therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile…
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE